Breaking News Instant updates and real-time market news.

FOMX

Foamix

$3.85

0.33 (9.38%)

08:14
11/04/19
11/04
08:14
11/04/19
08:14

Foamix announces peer review publication on studies FX2014-04 and FX2014-05

Foamix Pharmaceuticals announced the peer review publication of the long term open label safety portions of studies FX2014-04 and FX2014-05 in the Journal of Clinical and Aesthetic Dermatology, or JCAD. Studies 04 and 05 were conducted by Foamix to support the New Drug Application submission of AMZEEQTM topical foam, which was approved by the U.S. FDA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. The open-label safety portions of Studies 04 and 05 enrolled a total of 657 patients, all of whom had completed 12 weeks of AMZEEQ topical foam, 4% or vehicle treatment in the preceding double-blind phases of these studies. Patients continued for up to an additional 40 weeks of open-label treatment with AMZEEQ. Of those enrolled in this safety study, 291 completed a total of 52 weeks of therapy. Subject satisfaction with AMZEEQ treatment remained high when re-assessed at Week 52 which was consistent with scores obtained at Week 12.

FOMX Foamix
$3.85

0.33 (9.38%)

06/11/19
LEHM
06/11/19
INITIATION
Target $10
LEHM
Overweight
Foamix initiated with an Overweight at Barclays
Barclays analyst Balaji Prasad started Foamix Pharmaceuticals with an Overweight rating and $10 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
10/08/19
CANT
10/08/19
NO CHANGE
Target $15
CANT
Overweight
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
Cantor Fitzgerald analyst Louise Chen says her 25 physician survey supports her positive view on the market opportunity for Foamix's FMX10. If approved, FMX101 has the potential to address a significant unmet need in the treatment of moderate-to-severe acne, which remains a difficult condition, Chen tells investors in a research note. She reiterates an Overweight rating on Foamix shares with a $15 price target ahead of the upcoming FDA action date for FMX101 on October 20. The analyst thinks the Street is underestimating the uptake of acne drugs.
10/16/19
LEHM
10/16/19
NO CHANGE
Target $10
LEHM
Overweight
Barclays likes Foamix setup into October 20 FDA action date
Barclays analyst Balaji Prasad highlights Foamix Pharmaceuticals' key upcoming FDA action date of October 20 for FMX-101 in acne. The analyst says ~75% of his $10 price target is derived from FMX-101, and that approval could add another $2, or 320% potential upside from current share levels. The analyst sees a 90% probability of success and forecasts 2025 risk adjusted sales of $202M. Prasad continues to like Foamix's risk/reward setup going into the October 20 PDUFA and he reiterates an Overweight rating on the shares.
10/21/19
HCWC
10/21/19
NO CHANGE
Target $11
HCWC
Buy
Foamix price target raised to $11 from $10 at H.C. Wainwright
Foamix Pharmaceuticals last week arguably the most successful week in its history as a public company, with FMX101 being approved by the FDA for treatment of moderate-to-severe acne vulgaris and FMX103 being accepted for review by the agency as a treatment for moderate-to-severe papulopustular rosacea, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on the shares and boosted his price target to $11 from $10.

TODAY'S FREE FLY STORIES

SNAP

Snap

$14.45

0.22 (1.55%)

05:19
12/13/19
12/13
05:19
12/13/19
05:19
Upgrade
Snap upgraded to Outperform from Market Perform at JMP Securities »

JMP Securities analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$92.79

-2.2 (-2.32%)

05:16
12/13/19
12/13
05:16
12/13/19
05:16
Recommendations
Incyte analyst commentary  »

Incyte risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

PCG

PG&E

$11.75

-0.38 (-3.13%)

05:14
12/13/19
12/13
05:14
12/13/19
05:14
Hot Stocks
PG&E files amended plan of reorganization »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

05:12
12/13/19
12/13
05:12
12/13/19
05:12
Recommendations
Sarepta price target raised to $210 from $185 at Piper Jaffray »

Piper Jaffray analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOVE

Lovesac

$11.81

-2.68 (-18.50%)

05:07
12/13/19
12/13
05:07
12/13/19
05:07
Downgrade
Lovesac rating change  »

Lovesac downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 19

    Dec

TDOC

Teladoc

$77.06

-0.36 (-0.46%)

05:04
12/13/19
12/13
05:04
12/13/19
05:04
Initiation
Teladoc initiated  »

Teladoc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTMI

TTM Technologies

$13.79

0.19 (1.40%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Upgrade
TTM Technologies rating change  »

TTM Technologies upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$34.41

0.41 (1.21%)

05:01
12/13/19
12/13
05:01
12/13/19
05:01
Downgrade
Federated Investors rating change  »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMK

AssetMark Financial

$27.31

0.42 (1.56%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
AssetMark Financial rating change  »

AssetMark Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCTR

Victory Capital

$21.68

0.235 (1.10%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Downgrade
Victory Capital rating change  »

Victory Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$47.08

0.395 (0.85%)

05:00
12/13/19
12/13
05:00
12/13/19
05:00
Upgrade
Eaton Vance rating change  »

Eaton Vance upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$60.47

-0.37 (-0.61%)

04:59
12/13/19
12/13
04:59
12/13/19
04:59
Initiation
Papa John's initiated  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

NGLOY

Anglo American

$0.00

(0.00%)

04:57
12/13/19
12/13
04:57
12/13/19
04:57
Downgrade
Anglo American rating change  »

Anglo American assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACB

Aurora Cannabis

$2.61

0.15 (6.10%)

, CRON

Cronos Group

$7.31

0.49 (7.18%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
MJBizDaily to hold a conference »

Marijuana Business…

ACB

Aurora Cannabis

$2.61

0.15 (6.10%)

CRON

Cronos Group

$7.31

0.49 (7.18%)

NFX

Newfield Exploration

$0.00

(0.00%)

CGC

Canopy Growth

$21.14

0.84 (4.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$287.22

3.3 (1.16%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
ASML management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

04:55
12/13/19
12/13
04:55
12/13/19
04:55
General news
Retail Sales less autos to be reported at 08:30 »

November Retail Sales…

04:55
12/13/19
12/13
04:55
12/13/19
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/13/19
12/13
04:55
12/13/19
04:55
General news
Breaking General news story  »

New York Federal Reserve…

UBX

Unity Biotechnology

$8.30

0.61 (7.93%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Recommendations
Unity Biotechnology analyst commentary  »

Unity Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

COUP

Coupa Software

$136.91

-7.2 (-5.00%)

, CRWD

Crowdstrike

$47.25

-0.49 (-1.03%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
FBN to hold a bus tour »

17th Semi-Annual Silicon…

COUP

Coupa Software

$136.91

-7.2 (-5.00%)

CRWD

Crowdstrike

$47.25

-0.49 (-1.03%)

FEYE

FireEye

$16.33

0.095 (0.59%)

FSCT

ForeScout

$34.24

0.73 (2.18%)

FTNT

Fortinet

$104.45

0.29 (0.28%)

NOW

ServiceNow

$265.76

-1.665 (-0.62%)

NTAP

NetApp

$62.73

2.12 (3.50%)

PFPT

Proofpoint

$112.97

-0.03 (-0.03%)

PSTG

Pure Storage

$16.50

0.16 (0.98%)

QLYS

Qualys

$84.80

0.46 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 17

    Dec

  • 06

    Jan

  • 08

    Jan

  • 13

    Jan

  • 10

    Mar

  • 11

    Mar

  • 09

    Dec

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
BTIG biotech analysts to hold an analyst/industry conference call »

Biotech Analysts, along…

EA

Electronic Arts

$105.08

1.9 (1.84%)

, ATVI

Activision Blizzard

$58.60

2.12 (3.75%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

EA

Electronic Arts

$105.08

1.9 (1.84%)

ATVI

Activision Blizzard

$58.60

2.12 (3.75%)

GME

GameStop

$5.58

0.05 (0.90%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$125.33

2.95 (2.41%)

UBSFY

Ubisoft

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

OGI

Organigram

$2.57

(0.00%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Organigram management to meet with Cantor Fitzgerald »

Analyst Pablo Zuanic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ABB

ABB

$23.62

0.685 (2.99%)

, MMM

3M

$168.54

-0.19 (-0.11%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Wolfe Research to hold a field trip »

European Multi-Industry…

ABB

ABB

$23.62

0.685 (2.99%)

MMM

3M

$168.54

-0.19 (-0.11%)

SCHN

Schnitzer Steel

$22.39

0.22 (0.99%)

UTX

United Technologies

$149.49

2.2 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

TTWO

Take-Two

$125.33

2.95 (2.41%)

04:55
12/13/19
12/13
04:55
12/13/19
04:55
Conference/Events
Take-Two management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.